S D Berry1, Y Zhu, H Choi, D P Kiel, Y Zhang. 1. Institute for Aging Research, Hebrew SeniorLife & Department of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA. sarahberry@hrca.harvard.edu
Abstract
SUMMARY: We found the risk of hip fracture was transiently elevated around twofold shortly after initiation of a loop or thiazide diuretic drug in a case-crossover and case-control study. No statistical association was found following the initiation of a comparator medication: ACE inhibitors. Awareness of these short-term risks may reduce hip fractures. INTRODUCTION: Little is known about the acute effects of initiating a diuretic drug on risk of fracture. We evaluated the relationship between initiating a diuretic drug and the occurrence of hip fracture. METHODS: The study sample included 2,118,793 persons aged ≥50 years enrolled in The Health Improvement Network (THIN) between 1986 and 2010. The effect of a new start of a diuretic drug or comparator medication (ACE inhibitor) on risk of hip fracture was assessed using a case-crossover and case-control study during the 1-7, 8-14, 15-21, and 22-28 days following drug initiation. RESULTS: Included were 28,703 individuals with an incident hip fracture over a mean of 7.9 years follow-up. In the case-crossover study, the risk of experiencing a hip fracture was increased during the first 7 days following loop diuretic drug initiation (OR = 1.8; 95 % CI, 1.2, 2.7). The elevated risk did not continue during the 8-14, 15-21, or 22-28 days following drug initiation. For thiazide diuretics, the risk of hip fracture was elevated 8-14 days after drug initiation (OR = 2.2; 95 % CI, 1.2, 3.9). No such association was observed in the 1-7, 15-21, or 22-28 days following thiazide drug initiation. ACE inhibitor initiation was not associated with a statistically significant increased risk of hip fracture. Similar results were observed using a case-control study. CONCLUSIONS: The risk of hip fracture was transiently elevated around twofold shortly after the new start of a loop or thiazide diuretic drug. Awareness of these short-term risks may reduce hip fractures and other injurious falls in vulnerable adults.
SUMMARY: We found the risk of hip fracture was transiently elevated around twofold shortly after initiation of a loop or thiazide diuretic drug in a case-crossover and case-control study. No statistical association was found following the initiation of a comparator medication: ACE inhibitors. Awareness of these short-term risks may reduce hip fractures. INTRODUCTION: Little is known about the acute effects of initiating a diuretic drug on risk of fracture. We evaluated the relationship between initiating a diuretic drug and the occurrence of hip fracture. METHODS: The study sample included 2,118,793 persons aged ≥50 years enrolled in The Health Improvement Network (THIN) between 1986 and 2010. The effect of a new start of a diuretic drug or comparator medication (ACE inhibitor) on risk of hip fracture was assessed using a case-crossover and case-control study during the 1-7, 8-14, 15-21, and 22-28 days following drug initiation. RESULTS: Included were 28,703 individuals with an incident hip fracture over a mean of 7.9 years follow-up. In the case-crossover study, the risk of experiencing a hip fracture was increased during the first 7 days following loop diuretic drug initiation (OR = 1.8; 95 % CI, 1.2, 2.7). The elevated risk did not continue during the 8-14, 15-21, or 22-28 days following drug initiation. For thiazide diuretics, the risk of hip fracture was elevated 8-14 days after drug initiation (OR = 2.2; 95 % CI, 1.2, 3.9). No such association was observed in the 1-7, 15-21, or 22-28 days following thiazide drug initiation. ACE inhibitor initiation was not associated with a statistically significant increased risk of hip fracture. Similar results were observed using a case-control study. CONCLUSIONS: The risk of hip fracture was transiently elevated around twofold shortly after the new start of a loop or thiazide diuretic drug. Awareness of these short-term risks may reduce hip fractures and other injurious falls in vulnerable adults.
Authors: Jonathan Gribbin; Richard Hubbard; John Gladman; Chris Smith; Sarah Lewis Journal: Pharmacoepidemiol Drug Saf Date: 2011-07-11 Impact factor: 2.890
Authors: Sarah D Berry; Murray A Mittleman; Yuqing Zhang; Daniel H Solomon; Lewis A Lipsitz; Elizabeth Mostofsky; Dana Goldense; Douglas P Kiel Journal: Pharmacoepidemiol Drug Saf Date: 2012-03-16 Impact factor: 2.890
Authors: Mariette W C J Schoofs; Marjolein van der Klift; Albert Hofman; Chris E D H de Laet; Ron M C Herings; Theo Stijnen; Huibert A P Pols; Bruno H Ch Stricker Journal: Ann Intern Med Date: 2003-09-16 Impact factor: 25.391
Authors: Daichi Shimbo; C Barrett Bowling; Emily B Levitan; Luqin Deng; John J Sim; Lei Huang; Kristi Reynolds; Paul Muntner Journal: Circ Cardiovasc Qual Outcomes Date: 2016-05-10
Authors: Mary E Tinetti; Ling Han; David S H Lee; Gail J McAvay; Peter Peduzzi; Cary P Gross; Bingqing Zhou; Haiqun Lin Journal: JAMA Intern Med Date: 2014-04 Impact factor: 21.873
Authors: Rosilene Motta Elias; Maria Aparecida Dalboni; Ana Carolina E Coelho; Rosa M A Moysés Journal: Curr Osteoporos Rep Date: 2018-12 Impact factor: 5.096
Authors: Karen L Margolis; Lisa Palermo; Eric Vittinghoff; Gregory W Evans; Hal H Atkinson; Bruce P Hamilton; Robert G Josse; Patrick J O'Connor; Debra L Simmons; Margaret Tiktin; Ann V Schwartz Journal: J Gen Intern Med Date: 2014-08-16 Impact factor: 5.128
Authors: Michelle R Denburg; Mary B Leonard; Kevin Haynes; Shamir Tuchman; Gregory Tasian; Justine Shults; Lawrence Copelovitch Journal: Clin J Am Soc Nephrol Date: 2014-10-23 Impact factor: 8.237
Authors: Jason M Nagata; Neville H Golden; Mary B Leonard; Lawrence Copelovitch; Michelle R Denburg Journal: J Bone Miner Res Date: 2017-01-19 Impact factor: 6.741